Objective:
To discuss the evolving applications of retinal gene therapy for common retinal diseases, particularly in the context of recent advancements.
Key Findings:
- The only FDA-approved retinal gene therapy is Luxturna for inherited retinal dystrophy associated with RPE65 mutations, approved in 2017.
- A single intravitreal injection of Ixo-vec showed sustained therapeutic activity for 3.5 years in a case study involving ex vivo donor eye tissue.
- Next-generation AAV capsids are being engineered to enhance retinal penetration and transduction efficiency, addressing current limitations.
Interpretation:
Limitations:
- Risks include inflammation, immunogenicity, and procedural risks associated with surgical delivery methods, such as retinal detachment and hemorrhage.
- Current AAV vectors have restricted payload capacity and difficulties in penetrating vitreoretinal barriers.
Conclusion:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.